Exelixis | EXEL - Current Assets


Exelixis reported $1.32B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Akebia Therapeutics USD 220.78M 8.77M Sep/2026
Amgen USD 34.36B 598M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Bayer EUR 39.6B 5.96B Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
Eisai JPY 866.82B 16.2B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Exelixis USD 1.32B 70.8M Sep/2026
Genmab DKK 2.8B 228M Jun/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
MacroGenics USD 295.08M 26.61M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Moderna USD 7.34B 1.53B Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sanofi EUR 31.52B 1.36B Jun/2026
Takeda JPY 3T 153.11B Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Xencor USD 498.66M 24.55M Sep/2026